Recommended

New webinar with Fujifilm: Monocyte activation test (MAT): Insight into examining regulations and markets prospects
New webinar: The path to optimisation in pharmaceutical microbiology
Join our webinar: An alternative medium to support sterility testing using the Growth Direct® Rapid Sterility System
Discover more in our new application note: validating recombinant cascade reagents in 3 simple steps
news

Genmab appoints new EVP and Chief Technology Officer

The new member of Genmab’s Executive Committee brings over 30 years of international biopharmaceutical experience to the role.

Genmab Rayne

Credit: ArDanMe / Shutterstock.com

Rayne Waller will be joining the Genmab A/S Executive Committee as Executive Vice President and Chief Technology Officer.

The company stated that the creation of this new role in its committee will support Genmab’s innovation development as a biotech firm.

In addition, Executive Vice President and Chief Operating Officer Anthony Mancini will step down, “to pursue other opportunities”, according to the company.

Jan van de Winkel, PhD, Chief Executive Officer of Genmab remarked that having Rayne on the committee will strengthen Genmab’s commitment to the future of its “innovative mid- to late-stage clinical programmes”. He is “confident” in Rayne’s ability to “execute towards our 2030 vision to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO®) antibody medicines”.

Genmab’s new EVP and Chief Technology Officer

As Executive Vice President and Chief Technology Officer for Genmab, Rayne will help to strengthen the biotech’s technical operations capabilities and lead the manufacturing and supply chain capabilities of Genmab’s proprietary programmes”

As Executive Vice President and Chief Technology Officer for Genmab, Rayne will help to strengthen the company’s technical operations capabilities and lead the manufacturing and supply chain capabilities of the biotech’s proprietary programmes. He will steer these through the three main developments stages, from preclinical to the clinical and commercial phases, Genmab stated.

The company highlighted that Rayne has over three decades of experience in the international biopharmaceutical sector. This includes chemistry, manufacturing and controls (CMC) operations, as well as supply chain management, corporate governance, and “oversight of multi-product, multi-ton production and multi-billion-dollar inventory management”.

Previously, Rayne held the role of Chief Operating Officer at Capsida Biotherapeutics. During his career, he also worked at Amgen for 27 years. In this position, Rayne held roles “of increasing scope and responsibilities in product production, packaging, distribution, logistics, and plant and supply chain management”, Genmab confirmed.

In his new position, Rayne will join the rest of Genmab’s Executive Committee, which includes Chief Development Officer Dr Judith Klimovsky and Chief Medical Officer Dr Tahi Ahmadi.